Introduction: Introduction: Folate metabolism, play an important role in DNA methylation during proliferation and differentiation of tumor cells through methylenetetrahydrofolate reductase (MTHFR C677T) enzyme has been reported in variety of tumors . Present study has been designed with the aims evaluate the genetic heterogenicity and “risk factor” in heterozygous condition after calculating the frequency of CT genotypes in ovarian cancer patients, and also develop correlation with cellular proliferation (histopathology) in the same

Material and Method: Clinically diagnosed cases (n=125) of ovarian cancer patients with same age matched controls (n=137) were included in the present study. Total (5.0) ml sterile peripheral blood samples were collected and stored at -80°C till further process i.e. isolation of DNA and quantified by Nanodrop spectrophotometer (at wavelengths between 260-280 nm). ARMS-PCR was used for SNP analysis in cancer patients and compare with native controls (lack of familial history of cancer).

Results: Significant findings (p< 0.0002) reveals, 37.5 % frequency of genotype (677CT) were observed in heterogynous condition with Tm value of 83.50 and as compared to the 677TCC genotype (Tm 82.83) between cases controls. condition in ovarian cases. Interestingly, the frequency (33.33%) in heterozygous condition (CT genotype), highest recoded in germ cell tumors and minimal frequency (27.27%) were observed in surface epithelial tumors. Histopathological showing relevant correlation during onset of disease between the frequency (40%) in homozygous (TT rare genotypes) in sex-cord stromal tumors and risk factor (CT genotype) in germ cell tumors.

Conclusion: The present study demonstrates a significant differences in the frequency values between CT and TT genotypes that increase genetic susceptibility with increase “risk factor” in sex- cord stromal tissue in ovarian tumors due to substitution of nucleotide cysteine to thymidine in heterozygous condition (C→T) due to point mutation in folate metabolism associated MTHFR gene polymorphism to reduce 50% intracellular folate contents may increase risk for the development of ovarian cancers in the population of Bihar, hence, MTHFR C677T polymorphism act as potential biomarker for early diagnosis in cancer.

Keywords: Ovarian Cancer; MTHFR C677T Polymorphism; Histopathology; ARMS-PCR

References

1. Bray F., et al. “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries”. Ca-A Cancer Journal for Clinicians 6 (2018): 394-424.
2. Momenimovahed Z., et al. “Ovarian cancer in the world: epidemiology and risk factors”. International Journal of Women's Health 11 (2019): 287-299.
3. Chan JK., et al. “Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?” Obstetrics and Gynaecology 1 (2003): 156-161.
4. Kurman Robert J., et al. “World Health Organization Classification of Tumors of the Female Reproductive Organs. 4^th, International Agency for Research on Cancer (2014).
5. Wentzensen N., et al. “Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium”. Journal of Clinical Oncology 24 (2016): 2888-2898.
6. Giovannucci E., et al. “Folate, methionine, and alcohol intake and risk of colorectal adenoma”. Journal of the National Cancer Institute 11 (1993): 875-884.
7. Tworoger SS., et al. “Intake of folate and related nutrients in relation to risk of epithelial ovarian cancer”. American Journal of Epidemiology 12 (2006): 1101-1111.
8. Saxena Ajit K., et al. “ARMS-PCR based SNP analysis of MTHFR C677T allele using Syber green in pancreatic tumor”. British Journal Of Medical and Health Research 12 (2016): 1-6.
9. Ye S., et al. “An efficient procedure for genotyping single nucleotide polymorphisms”. Nucleic Acids Research17 (2001): E88-98.
10. Saxena Ajit K. et al. “Evaluation of Methylenetetrahydrofolate reductase C677T gene polymorphism associated risk factor in the patients of recurrent pregnancy loss”. International Journal of Medical Genetics and Genomics2 (2012): 25-28.
11. Saxena Ajit K., et al. “Penetrance of Methylene Tetrahydrofolate Reductase C677T Gene Polymorphism and Karyotypic Variations Associated Increase Genetic Susceptibility in the cases of Congenital Heart Defects”. Biomedical Journal of Scientific and Technical Research 1 (2021): 30051-30057.
12. Ma J., et al. “Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer”. Cancer Research 6 (1997): 1098-1102.
13. GK Singh., et al. “p53 gene inactivation modulates methylenetetrahydrofolate C677T gene polymorphism associate risk factor for the development of cervical carcinoma-A tissue specific genetic heterogeneity”. The Journal of Clinical and Experimental Oncology 23 (2009): 167-178.
14. Ali AT., et al. “Epidemiology and risk factors for ovarian cancer”. Przeglad Menopauzalny 2 (2023): 93-104.
15. Lheureux S., et al. “Epithelial ovarian cancer: Evolution of management in the era of precision medicine”. CA Ca-A Cancer Journal for Clinicians 4 (2019): 280-304.
16. Anupma Singh., et al. “In Human allele specific variation of MTHFR C677T and A1298C associate risk factor for the Development of Ovarian Cancer”. Journal of Experimental Therapeutics and Oncology 1 (2015): 67-70.
17. Lheureux S., et al. “Epithelial ovarian cancer: Evolution of management in the era of precision medicine”. Ca-A Cancer Journal for Clinicians 4 (2019): 280-304.
18. Saxena Ajit K., et al. “Differential expression of Vimentin gene modulated by MTHFR C677T gene polymorphism in circulating tumor cells isolated from breast cancer patient”. Genetics and Molecular Research1 (2024): 1-10.
19. Viel A., et al. “Loss of heterozygosity at the 5,10-methylenetetrahydrofolate reductase locus in human ovarian carcinomas”. British Journal of Cancer 8 (1997): 1105-1110.
20. Timmermans M., et al. “No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands”. The European Journal of Cancer  88 (2018): 31-37.
21. Zhou L., et al. “Ovarian endometrioid carcinoma and clear cell carcinoma: A 21-year retrospective study”. Journal of Ovarian Research 14 (2021): 63.
22. Clarke-Pearson DL. “Clinical practice. Screening for ovarian cancer”. The New England Journal of Medicine 361 (2009): 170-177.

Citation

Citation: Ajit Kumar Saxena., et al. “Significant Association of Methylenetetrahydrofolate Reductase (MTHFR) C677T Polymorphism Increasing Risk Factor in Adenocarcinoma of Ovary in Indian Population of Bihar”.Acta Scientific Cancer Biology 9.2 (2025): 20-25.

Copyright

Copyright: © 2025 Ajit Kumar Saxena., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.